“非典”疫情打击了旅游、交通、餐饮等行业,同时给生物医药行业带来了机遇。恐惧“非典”疫情蔓延得更快,而且显然影响到了人们的交易热情,受此影响,沪深股市前些日的上升行情不幸夭折,但生物医药类上市公司大多一枝独秀涨势喜人。医药板块的整体上扬与“非典”有很大的相关性。在90多家医药类上市公司里,有1/3的上市公司牵扯到“非典”药品的生产,随着卫生部公布对预防和治疗“非典”的药物种类,与“非典”有关的公司争相表现。但“非典”对公司业绩有多大的影响,要看疫情的变化情况。 The “SARS” epidemic has hit the travel, transportation and catering sectors and brought opportunities to the biomedical industry. Fear of “SARS” epidemic spread more quickly, and obviously affect people’s enthusiasm for the transaction, affected by this, the Shanghai and Shenzhen stock market rise unfortunately unfortunate market, but most of the successful biomedical listed companies gratifying. The overall upward trend of the pharmaceutical sector has a lot to do with SARS. In the more than 90 pharmaceutical listed companies, one third of public listed companies involved in the production of SARS drugs. As the Ministry of Health announced the types of drugs for preventing and treating “SARS”, the “SARS” related company dispute Phase performance. However, the impact of SARS on corporate performance depends on the changes in the outbreak.